Literature DB >> 24947681

Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

A Matito1, I Alvarez-Twose, J M Morgado, L Sánchez-Muñoz, A Orfao, L Escribano.   

Abstract

Clonal mast cell disorders comprise a heterogeneous group of disorders characterized by the presence of gain of function KIT mutations and a constitutively altered activation-associated mast cell immunophenotype frequently associated with clinical manifestations related to the release of mast cells mediators. These disorders do not always fulfil the World Health Organization (WHO)-proposed criteria for mastocytosis, particularly when low-sensitive diagnostic approaches are performed. Anaphylaxis is a frequent presentation of clonal mast cell disorders, particularly in mastocytosis patients without typical skin lesions. The presence of cardiovascular symptoms, e.g., hypotension, occurring after a hymenoptera sting or spontaneously in the absence of cutaneous manifestations such as urticaria is characteristic and differs from the presentation of anaphylaxis in the general population without mastocytosis.

Entities:  

Mesh:

Year:  2014        PMID: 24947681     DOI: 10.1007/s11882-014-0450-8

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  123 in total

1.  Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells.

Authors:  H R Katz; M B Raizman; C S Gartner; H C Scott; A C Benson; K F Austen
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

2.  IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis.

Authors:  A Matito; B Bartolomé-Zavala; I Alvarez-Twose; I Sánchez-Matas; L Escribano
Journal:  Allergy       Date:  2009-12-11       Impact factor: 13.146

3.  Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.

Authors:  J A Douglass; K Carroll; A Voskamp; P Bourke; A Wei; R E O'Hehir
Journal:  Allergy       Date:  2009-11-04       Impact factor: 13.146

4.  Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells.

Authors:  Sonia Varadaradjalou; Frédéric Féger; Nathalie Thieblemont; Nadine Ben Hamouda; Jean-Marie Pleau; Michel Dy; Michel Arock
Journal:  Eur J Immunol       Date:  2003-04       Impact factor: 5.532

5.  Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.

Authors:  Friedrich Wimazal; Philipp Geissler; Patrik Shnawa; Wolfgang R Sperr; Peter Valent
Journal:  Int Arch Allergy Immunol       Date:  2011-11-25       Impact factor: 2.749

6.  Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia.

Authors:  W R Sperr; J H Jordan; M Baghestanian; H P Kiener; P Samorapoompichit; H Semper; A Hauswirth; G H Schernthaner; A Chott; S Natter; D Kraft; R Valenta; L B Schwartz; K Geissler; K Lechner; P Valent
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

7.  Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.

Authors:  Thorsten Klampfl; Ashot Harutyunyan; Tiina Berg; Bettina Gisslinger; Martin Schalling; Klaudia Bagienski; Damla Olcaydu; Francesco Passamonti; Elisa Rumi; Daniela Pietra; Roland Jäger; Lisa Pieri; Paola Guglielmelli; Ilaria Iacobucci; Giovanni Martinelli; Mario Cazzola; Alessandro M Vannucchi; Heinz Gisslinger; Robert Kralovics
Journal:  Blood       Date:  2011-04-29       Impact factor: 22.113

8.  Mast cells are required for experimental oral allergen-induced diarrhea.

Authors:  Eric B Brandt; Richard T Strait; Dan Hershko; Quan Wang; Emily E Muntel; Troy A Scribner; Nives Zimmermann; Fred D Finkelman; Marc E Rothenberg
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Authors:  B J Longley; L Tyrrell; S Z Lu; Y S Ma; K Langley; T G Ding; T Duffy; P Jacobs; L H Tang; I Modlin
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

10.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).

Authors:  Luis Escribano; Beatriz Diaz-Agustin; Antonio López; Rosa Núñez López; Andrés García-Montero; Julia Almeida; Aranzazu Prados; Miguel Angulo; Sonia Herrero; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2004-03       Impact factor: 3.058

View more
  8 in total

Review 1.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 2.  Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-05

Review 3.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

Review 4.  Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.

Authors:  David González-de-Olano; Almudena Matito; Alberto Orfao; Luis Escribano
Journal:  F1000Res       Date:  2016-11-14

Review 5.  Insights in Anaphylaxis and Clonal Mast Cell Disorders.

Authors:  David González-de-Olano; Iván Álvarez-Twose
Journal:  Front Immunol       Date:  2017-07-10       Impact factor: 7.561

6.  Case Report: Mastocytosis: The Long Road to Diagnosis.

Authors:  Tiago Azenha Rama; Diana Martins; Nuno Gomes; Jorge Pinheiro; Ana Nogueira; Luís Delgado; José Luís Plácido; Alice Coimbra
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

7.  Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.

Authors:  Iolanda Conde-Fernandes; Rita Sampaio; Filipa Moreno; José Palla-Garcia; Maria Dos Anjos Teixeira; Inês Freitas; Esmeralda Neves; Maria Jara-Acevedo; Luis Escribano; Margarida Lima
Journal:  Allergy Asthma Clin Immunol       Date:  2017-04-24       Impact factor: 3.406

Review 8.  Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Petri T Kovanen; Emir Hadzijusufovic; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Lawrence B Schwartz; K Frank Austen; Dean D Metcalfe; Stephen J Galli
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.